Assembly Biosciences (STU:V7B) Moat Score: 3/10 (As of Jul. 11, 2026)


STU:V7B Assembly Biosciences Inc STU:V7B
31 GF Score
Price €24.00
GF Value €17.38
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Assembly Biosciences Moat Score?

Assembly Biosciences STU:V7B -1.23% 31 Moat Score is 3 as of Jul. 11, 2026. GuruFocus rates STU:V7B with a GF Score™ of 31/100 and a GF Value™ of €17.38 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,395 Biotechnology companies, Assembly Biosciences ranks better than 75.56% on this metric.

Assembly Biosciences has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Assembly Biosciences has No Moat: Assembly Biosciences Inc has some valuable intellectual property in the biotech sector, but faces intense competition and high R&D costs. The company lacks market leadership, strong brand strength, and significant customer switching costs, resulting in a very weak competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Assembly Biosciences might have No Moat - Very weak/transient advantages.

Assembly Biosciences  (STU:V7B) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Assembly Biosciences Moat Score Related Terms

STU:V7B vs CTNM, PRTA, RGNX: Moat Score Comparison

For the Biotechnology subindustry, Assembly Biosciences's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Assembly Biosciences Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Assembly Biosciences's Moat Score distribution charts can be found below:

* The bar in red indicates where Assembly Biosciences's Moat Score falls into.


STU:V7B
31GF Score
Assembly Biosciences Inc STU:V7B
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Assembly Biosciences (STU:V7B) has a Moat Score of 3 as of Jul. 11, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Assembly Biosciences ranks #341 out of 1395 companies in the Biotechnology industry, placing it in the top 24.4%.
Is Assembly Biosciences' Moat Score too high?
Assembly Biosciences' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Assembly Biosciences' value of 3 is 50% above this industry median. Based on the distribution chart, Assembly Biosciences ranks #341 out of 1395 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Assembly Biosciences has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Assembly Biosciences' Moat Score compare to CTNM and PRTA?
According to the Biotechnology industry distribution chart, Assembly Biosciences ranks #341 out of 1395 companies for Moat Score. This places Assembly Biosciences in the top 24% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Assembly Biosciences' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,395 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Assembly Biosciences's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Assembly Biosciences's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Assembly Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Assembly Biosciences (STU:V7B) is currently considered Significantly Overvalued. The stock's GF Value™ is €17.38, compared to a current price of €24.00 — trading 38.1% above its estimated fair value. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Assembly Biosciences' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Assembly Biosciences (STU:V7B), the current Moat Score is 3 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Assembly Biosciences (STU:V7B) Overvalued in 2026?

Based on GuruFocus' analysis, Assembly Biosciences stock appears to be overvalued. The current stock price of €24.00 is trading 38.1% above its estimated GF Value™ of €17.38. GuruFocus considers Assembly Biosciences to be Significantly Overvalued.

Key valuation signals for STU:V7B:

  • Moat Score: 3
  • GF Value™: €17.38 vs. price of €24.00 (38.1% above fair value)
  • GF Score™: 31/100 with 3 warning signs
  • Industry Position: 50% above the Biotechnology median (#341 of 1395)

No single metric tells the full story. See the STU:V7B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Assembly Biosciences Business Description

Other Exchanges ASMB:USA
Address Two Tower Place, 7th Floor, South San Francisco, CA, USA, 94080
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
31GF Score

Get the complete analysis for STU:V7B

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€24.00
Price
€17.38
GF Value